Disclosure: we hold no position in PDPG either long or short and we have not been compensated for this article
Featured
Regen BioPharma Inc (OTCMKTS: RGBP) Major Reversal Brewing as Biotech Looks to Commercialize its Modified mRNA anti-cancer Vaccine & Accelerate Clinical Development of its NR2F6 Therapies
Published
10 months agoon
By
Boe Rimes
Regen BioPharma Inc (OTCMKTS: RGBP) has been steadily dropping since topping out at $0.0819 in September of last year. Now it looks like its oversold and ready for a major reversal and speculators are beginning to accumulate into the selling which is starting to wane at current levels. RGBP has a massive following of shareholders, many of them international that will jump on board at any hint that the bottom has been reached; once RGBP begins to move to the upside it could be fast and furious. The Company has accomplished a lot since the last time we reported on it when they had just accomplished a number of wins including going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities. More recently Regen began a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. They also announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA (small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
Microcapdaily has been reporting on RGBP since early last year. The last time we covered the Company we stated among other things: “RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.”
Regen BioPharma Inc (OTCMKTS: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.
Regen owns a valuable intelectuable property portfolio including 8 issued patents and 13 published patent applications. Zander Therapeutics, Inc. (a company under common control) has been granted an exclusive license to develop and commercialize IP controlled by the Company for non-human veterinary therapeutic use. Regen has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize “Antigen specific mRNA cellular cancer vaccines” for the treatment of pancreatic cancer and KCL Therapeutics, Inc. has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize certain intellectual property for the treatment of colon cancer.
The Company is led by CEO David Koos who has over 30 years of investment banking and venture capital experience. He has a deep knowledge of startup businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally, he has authored / co-authored numerous peer reviewed journal articles. Dr. Koos worked hard to get the filings up to date and get the Company compliant which has recently been completed with RGBP now “pink current”
https://twitter.com/TrelloThaGod/status/1509124476910374915
To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On February 11 RGBP announced it is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial series of pre-clinical studies required as part of an FDA IND submission. The patented technology (patent issued in Aug, 2021) is a cellular vaccine that uses a modified mRNA molecule expressing peptides of Survivin which are exposed to dendritic cells. These dendritic cells are then matured and infused into the cancer patient’s circulation where they are expected to home in on the cancer and destroy it. There are currently several clinical trials ongoing in the U.S. and Europe using Survivin as a vaccine for multiple different cancers which further supports this approach.
Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis (a form of programmed cell death that occurs in multicellular organisms) and regulation of cell cycle. These functional attributes make Survivin a unique protein regulating cell proliferation and cell death. Expression of Survivin in tumors correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumors. Therefore, Survivin is an important target for cancer vaccines and therapeutics. This technology has been out-licensed for use in pancreatic cancer which leaves Regen dozens of other potential indications.
In February Oncology Pharma, Inc. announced it will jointly develop Regen’s patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES (“MRNA Vaccines”). In April of 2021 ONPH was granted an exclusive right and license for the development and commercialization of the MRNA Vaccines for the treatment in humans of pancreatic cancer. The current intent is that IND (“Investigational New Drug Application”) enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing.
On March 10 RGBP announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes (the cell’s protein-making machinery).
Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. Dyo Biotechnologies has been contracted to assist Regen with the development of the above mentioned technology. Regen is in the process of drafting a new patent application pertaining to this intellectual property.
$RGBP Ichim himself, a professional in his field, stated clinicals would probably start in 1-2 years. That was PRIOR to Regen announcing its intention to fast track mRNA technologies.
Sell if you want but I’m staying $RGBPP long. pic.twitter.com/lSgKxaCe9h— The_Shit_Stacker (@StackerShit) March 29, 2022
For more on RGBP Subscribe Right Now!
Currently trading at a $28 million market valuation RGBP has 4,580,002,832 shares outstanding and a debt load that has caused significant dilution in the past. But RGBP is an exciting story developing in small caps, at current levels the selling pressure that decimated the share price from over $0.08 to half a penny is waning and many speculators are accumulating with a belief that a major reversal is about to happen. As we said, once RGBP begins to move to the upside it could be fast and furious. RGBP is no stranger to big moves and has runner in its blood skyrocketing to $0.0819 not once but twice in the past year alone. The stock is currently trading well below established support levels at $0.01 just a year ago and has a significant gap to fill from current levels. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article
You may like
-
Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer Immunotherapeutic Vaccine
-
Regen BioPharma Inc (OTCMKTS: RGBP) Under Accumulation as Biotech Sleeper Makes Major Reversal Northbound (A look at Intellectual Property / mRNA Vaccine)
-
Regen BioPharma Inc (OTCMKTS: RGBP) Northbound as Biotech Grows Valuable Patent Portfolio & Grants 2 Licenses to Oncology Pharma for $1.9 Million
-
Regen BioPharma Inc (OTCMKTS: RGBP) Heats Up as Biotech Up Lists & Signs LOI to Acquire Canary Oncoceutics, Inc
-
Regen BioPharma Inc (OTCMKTS: RGBP) Mega Runner as Biotech Moves Towards “Pink Current” & Cancer Vaccine Patent Approved
-
Regen BioPharma Inc (OTCMKTS: RGBP) Biotech Sleeper Sitting on a Major League Patent Portfolio
1 Comment
Leave a Reply
Cancel reply
Leave a Reply
Featured
Performance Drink Group (OTCMKTS: PDPG) Under Accumulation as New Controlling Shareholders Affect 300 million Share Reduction
Published
2 months agoon
December 8, 2022By
Boe Rimes
Performance Drink Group (OTCMKTS: PDPG) is making an explosive move up the charts in recent trading rocketing up from well under a penny to recent highs of $0.03 per share. The stock started running in August of this year off its $0.0006 lows and formed a new over $0.003 before the recent runup into copperland.
PDPG recently affected a massive share reduction cancelling 300 million shares that had been issued to the controlling shareholders, Leonard K. Armenta Jr., and Dave Lovatt with each one cancelling 150 million shares. This leaves an OS of just 114.7 million, 80 million of which are restricted and can’t be traded.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Performance Drink Group (OTCMKTS: PDPG) is an emerging force in the development, production, and distribution of unique Sports Nutrition and Energy Drink solutions. The company is currently targeting growth in shareholder value through both organic and strategic channels. PDPG recently launched its zero-calorie, zero-sugar energy supplement drink, the “Pro Boost”, a new 2 FL OZ (60 ml) zero-calorie, zero-sugar energy supplement drink, is now available to order. Pro Boost is available to order through proboostenergy.com and the Company has already begun taking pre-orders direct from retailers who see this as an explosive space to be entering. Consumers are able to place orders now through the website.
Performance Drink Group, Inc., (Formerly: Liberty International Holding Corporation) a Colorado corporation was registered in the state of Florida in June 1997, and was re-instated in Florida on January 22, 2021. On March 18, 2021 the Company was re-domiciled to the state of Colorado. On December 15, 2020, the 11th Judicial Circuit Court in Miami-Dade County, Florida entered an order appointing Small Cap Compliance, LLC, as custodian for PDPG. On December 16, 2020, Rhonda Keaveney was appointed as interim officer and director.
On January 11, 2021 the Company added a Convertible Preferred B series of stock. The Convertible Preferred B stock has 10,000,000 authorized shares at $0.0001 par value. Each share of Series B stock shall be convertible, at the option of the holder, into 4 times the sum of all shares of Common Stock outstanding and all other preferred shares outstanding, divided by the outstanding number of shares of Series B Stock
On January 8, 2021, for their services, Small Cap Compliance was issued 7,716,216 Preferred A shares and 1 Preferred B share. Those shares were subsequently sold to Supplement Group. On January 8, 2021, Rhonda Keaveney resigned as the Company’s CEO, Treasurer, Secretary, and Director and appointed David Lovatt as its CEO, Treasurer, Secretary, and Director and Leonard K. Armenta Jr. as its president.
On February 16, 2021, the Company issued 300,000,000 shares of Common stock to its officers for compensation:
- 150,000,000 to David Lovatt
- 150,000,000 to Leonard K. Armenta Jr
On March 23, 2021 the Company amended its articles of incorporation to change its name to Performance Drink Group, Inc. Also the 300 million shares were canceled.
Leonard K. Armenta Jr., the Company’s president is a highly adaptable Marketing, Operations and Sales Executive with twenty years of profit driven experience developing new business, launching new internal departments, growing sales, launching new marketing strategies and maximizing positive customer and athlete relations.
Dave Lovatt, the Company’s CEO is a President, Chief Executive Officer & Director at Torque Lifestyle Brands, Inc., a President, Chief Executive Officer & Director at GenTech Holdings, Inc. and a President & Chief Executive Officer at VClouds Ltd. He is on the Board of Directors at Torque Lifestyle Brands, Inc. and GenTech Holdings, Inc. Mr. Lovatt was previously employed as a Chief Operating Officer, Secretary & Director by Sun Kissed Industries, Inc., a Chairman & President by Mobile Media Unlimited Holdings, Inc., a Chairman & President by Sirrustec, Inc.
To Find out the inside Scoop on PDPG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The last press release from the Company came back in May when they announced “Pro Boost”, a new 2 FL OZ (60 ml) zero-calorie, zero-sugar energy supplement drink, is now available to order. Pro Boost is available to order through proboostenergy.com and the Company has already begun taking pre-orders direct from retailers who see this as an explosive space to be entering. Consumers are able to place orders now through the website and product will start to be delivered both to retailers and consumers alike from June 1, 2022.
In addition to energizers like Taurine, Malic Acid, N-Acetyl L-Tyrosine, Glucuronolactone, Caffeine, and L-Phenylalanine, Pro Boost features a robust burst of B Vitamins, including 100% of the recommended daily value for Niacin, 2,000% of the recommended daily value for Vitamin B6, 100% of the recommended daily value for Folic Acid, and 8,333% of the recommended daily value for Vitamin B12. Pro Boost contains no calories, no sugar, no GMO, no gluten, no artificial colors, and no preservatives.
Management is focused on driving sales of Pro Boost by targeting distribution through specialty-supplement retail, as well as the traditional grocery and convenience store space. The direct to consumer model via the Company’s website is said to also be crucial in the success of the product.
The Company recently announces that it had hired James Gracely to be the SVP of Beverage and his remit was wide ranging from new product innovations and launches through to the formation of joint ventures and the all important strategy of acquisition targeting. The new Senior VP stated: “Pro Boost will mobilize an often undervalued beverage consumer by focusing on the gamer/streamer community. Pro Boost will have a wide appeal in all classes of trade as we seek placement across a broad spectrum of high-impact high-volume retail end-points.”
For More on PDPG Subscribe Right Now!
Currently trading at a $2 million market valuation PDPG has a low float and moves fast rocketing up more than 200% on Wednesday alone. The Company is in good shape; “pink current” with very little debt of just $300k in total liabilities. Earlier this year PDPG launched “Pro Boost”, a new 2 FL OZ (60 ml) zero-calorie, zero-sugar energy supplement drink. The controlling shareholders; Leonard K. Armenta Jr., and Dave Lovatt recently cancelled 150 million shares each for a total of 300 million shares leaving a free trading float of just over 30 million shares. Currently under heavy accumulation PDPG is quickly attracting a fast-growing shareholder base who see big things coming here. We will be updating on PDPG when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PDPG.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Featured
Cosmos Holdings Inc (NASDAQ: COSM) Mammoth Short Squeeze Rising Fast as CEO Grigorios Siokas Buying More (COSM Rapid Growth Through Acquisition)
Published
2 months agoon
December 5, 2022By
Boe Rimes
Cosmos Holdings Inc (NASDAQ: COSM) is an enormous short squeeze that is rocketing up the charts while the overall market are weak. On Monday COSM was up over 10% at one point but closed at $0.57 up 6.5% while the Nasdaq lost just under 500 points on the day. COSM is quickly going viral and is currently among the top most trending stocks on Stocktwits, the top most mentioned stock on the sub reddit Short Squeeze, and there are dozens of Youtube channels reporting on it and private discord groups buying COSM from all over the world.
While COSM was shorted into oblivion the Company is strong recently reporting $12 million in revenues in Q3 as well as rapid growth through acquisition with 3 major acquisitions currently on the table. COSM is led by able CEO Grigorios Siokas, a high level pharmaceutical executive Mr. Siokas is a major shareholder in Ippokratis Pharmaceuticals, Thrakis Pharmaceuticals, Thessalias Pharmaceuticals, and ZED Pharma SA. Since 2019, Mr. Siokas has invested over $10.6M at an average price of $5.25 of his personal wealth into Cosmos. More recently Mr. Siokas acquired another 1,131,098 shares on Friday adding to the 481,079 shares acquired Thursday adding to his previous buy of 800,000 shares at $0.62 earlier last week. This comes after Mr. Siokas acquired 12.5 million shares price at $0.12 as part of a securities purchase agreement in October.
COSM Tuesday Update: COSM is coming back moving back over $0.50 in late day trading Tuesday. The stock saw a significant drop this morning after the Company filed an 8k on Monday that stated the board had approved several matters including: “(6) to authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at their discretion.” This does not mean COSM is going to do a reverse split. It means the BOD has approved it so they can affect a RS at their discretion if they need to. It’s certainly in managements best interest not to do a reverse stock split. However, the Nasdaq listing is more important so they will use it if they have to. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The group in engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in EU and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Management is focused on Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, and Local & Direct to Pharmacy Wholesale. Check out the Company’s latest presentation here.
In Q3, 2022 Cosmos reported $12 million in revenues and made a number of important advancements including raising $7.5 million via a public offering, entered into an agreement to restructure its warrents to avoid dilution, announced an agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus and much more.
COSM Rapid Growth Though Acquisition:
Cosmos has a plan for rapid growth through acquisition; currently the Company is evaluating acquisition targets that allows it to expand its distribution reach and/or vertically integrate into its supply chain of the products. COSM is also actively pursuing accretive acquisitions that offer long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure.
COSM acquisitions currently on the table:
- Entered into an LOI to acquire ZipDoctor Inc., a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists.
- Entered into an agreement to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome.
- Entered into a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.
https://twitter.com/MoonMarket_/status/1599850735323136000
Recent News: Cosmos Health Provides a Summary Regarding Recent Share Activity and Reiterates its Belief and Commitment to the Financial Strength and the Growth and Profitability of the Company
On December 2 COSM provided a summary regarding recent share activity, including the participation of CEO, Greg Siokas on all capital raises. Management reiterates its belief in the financial strength of Cosmos Health, and its commitment to the growth and profitability of the Company.
In February and October of 2022 Cosmos successfully conducted two separate rounds of financings, with the combined proceeds of $13.5M. Furthermore, the Company has noted significant exercises of warrants in the month of November. As such, management now expects that by the end of Year End 2022, debt should decline by roughly 50% versus prior year levels.
Mr. Siokas has not sold any shares and has no plans to sell any of his shares.
Greg Siokas, Chief Executive Officer of Cosmos Health stated, “I am excited to see Cosmos emerge in to in a stronger financial position. We have had two successful capital raises in 2022, both of which I happily participated in for a combined amount of $3M. Since 2019, I have invested over $10.6M at an average price of $5.25 of my personal assets in Cosmos, as I have always believed in its growth and profitability prospects. My interests have always been and will continue to be aligned with those of shareholders, and I am constantly working to make sure shareholder value is realized. Given our new financial stability, I am hopeful about the future of Cosmos and our ability to rapidly grow as an international health and wellness company with multiple strong brands. I want to thank our shareholders and our team members who have helped us through this journey.”
$COSM
Double check your accounts for permission to hypothecate (loan) out your shares. People have been reporting that the brokers turned this permission on without their knowledge.— Frank Benedetto (@benedetto_frank) December 5, 2022
For More on COSM Subscribe Right Now!
Currently trading at a $46 million market valuation COSM os is 83,797,481 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then. COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 10 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1. As for the Nasdaq delisting COSM appealed it and has (until otherwise annouinced) until January 23 to get the bid over $1 We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.
Featured
Global Developments, Inc., (OTCMKTS: GDVM) Blue Sky Breakout as VeeMost Reverse Merger Achieves 4th Advanced Specialization
Published
2 months agoon
December 2, 2022By
Boe Rimes
Global Developments, Inc., (OTCMKTS: GDVM) has had another amazing week as the stock continues to rocket northbound. GDVM has been under heavy accumulation ever since Mr. Melvin Ejiogu, an executive who is President of VeeMost Technologies became the controlling shareholder and instituted a new dilution policy, affected a massive share reduction and trapped the market makers who were seriously short. On Friday the stock closed at $0.0898, right off the day’s highs of $0.0899 on just under $1 million in dollar volume booking more than 100% gains over just the past week.
Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. One recent RM runners that stand out is HRBR which went from a few cents (where we first wrote about it) to $3 plus. GDVM is the perfect reverse merger candidate with a clean balance sheet and is debt free. We first gave the heads up on GDVM when the stock was around $0.003 at the end of October.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Global Developments, Inc., (OTCMKTS: GDVM) a Delaware corporation was incorporated in Delaware on December 9, 2004 as Autobahn International, Inc., changed its name to Global Developments Inc. on May 30, 2016, and changed its name to Global Developments Holdings, Inc. on September 20, 2018. The Company sought to focus on equity and debt financing opportunities and business acquisitions. The Company has not had any significant operations since 2012. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target businesses. The Company has not identified or selected any Business Combination. As of March 31, 2022, the Company has no significant operations. 36,000 in liabilities.
$GDVM majority control acquired and all outstanding debt purchased. I also purchased 12% of outstanding shares and returned them to the treasury. No dilution will occur. I’ll be sharing updates soon with everyone on our new journey.
— Melvin Ejiogu (@MelvinEjiogu) September 21, 2022
Mr. Melvin Ejiogu, GDVM controlling shareholder and CEO is also currently serving as the CEO and President of VeeMost Technologies. Mr. Ejiogu owns at least 76.56% of all shares of common stock issued and outstanding. He holds a bachelor’s degree in Business Administration with a specialty in Corporate Finance from the University of Akron in Ohio. Melvin also holds several top-level certifications in the I.T industry, and he is one of the few individuals who have earned the prestigious Cisco Certified Internetwork Expert (CCIE) certification. With over 25 years in the technology industry, Melvin has successfully blended his business acumen with his technical expertise, finding innovate ways to use technology to transform businesses and solve business issues.
In his partnership with Fit Technologies in Cleveland Ohio where he served as the Director of Business Development and Director for Technology Engineering, Melvin was instrumental in growing the company’s annual revenue from $8M to $28M in a few years. Melvin has provided services to the US Federal Courts, Internal Revenue Service (IRS), United States Airforce, Fidelity Group, and many more. Melvin contracted with AT&T Labs where he served as a Lead Principal Architect & Designer, designing, implementing, and securing network infrastructures and solutions for large government entities and enterprise customers. He is recognized as an expert in delivering Transformation Services to enterprise organizations and was key to AT&T’s multibillion dollar contract with the United States Airforce.
To Find out the inside Scoop on GDVM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
VeeMost Technologies is a technology service and integration firm with a solid track record of helping our customers design, use, and manage technology to improve business outcomes and transform their businesses. With our deep technical expertise in networking, collaboration, and cyber security, we design solutions to help our clients bridge the gap between legacy investments and new innovations. Some of these include on-premises, hybrid, to cloud architecture that support business requirements and goals. Our services enable us to modernize and manage cloud and on-premise environments as “one” for our customers, enabling them to scale seamlessly.
In November VeeMost announced its recent achievement of Cisco’s Advanced Enterprise Networks Architecture Specialization. Over the last 6 months, VeeMost has also achieved the Advanced Collaboration Architecture Specialization, Advanced SP Architecture Specialization, and Advanced Security Architecture Specialization. This puts VeeMost Technologies on a path to becoming a Cisco Gold Integrator.
VeeMost Technologies has again proven to have the ability to provide sophisticated, value-added Cisco solutions through our in-depth sales capabilities, technology skills, and service offerings. The Cisco Advanced Enterprise Networks Architecture Specialization gives VeeMost Technologies the expertise and experience to assist clients in automating application rollouts to reduce risk and free up client IT staff, managing cloud services to enable fast adoptions, broad partner support, and on-demand scale, and virtualizing third-party applications and delivering services on any platform. Congratulations to all VeeMost Technologies Engineers who had their share in these recent achievements and successes.
VeeMost CEO Melvin Ejiogu said: “Our customers rely heavily on technology. This recent specialization achievement along with the previous three allows us to connect our client’s distributed workforce securely and reliably with Cisco’s solutions, helping keep their business resilient and agile while focusing on speed-to-value in every client engagement. Most importantly, this allows us to target those fortune 500 companies who only do business with Cisco gold partners. It is only a matter of time before the word about our expertise and our customer-first approach gets around.”
For More on GDVM Subscribe Right Now!
Currently trading at a $27 million market valuation GDVM OS is 368,333,637 down from 3.5 billion in September. The stock is moving up steadily on a locked float as the market makers scramble for shares in an effort to cover their naked short positions which are now seriously underwater. GDVI is moving northbound with no resistance whatsoever and nobody is selling as this short squeeze heats up fast. We will be updating on GDVM when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in GDVM either long or short and we have not been compensated for this article.
Street Watch

Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) Running as Company Meets Requirements to Trade in US and Short Covering Rally Intensifies

Evofem Biosciences Inc (OTCMKTS: EVFM) Steady Rise Northbound as Co Uplists to OTCQB Venture & Phexxi Approved in Nigeria While Sales Pick Up Rapidly

VNUE Inc (OTCMKTS: VNUE) Big Move as Co Partners with Kokku to Bring VNUE Festival & Multi-Stage Experience on Roblox and to Uplist to National Exchange

Revlon, Inc. (OTCMKTS: REVRQ) Q Stock Hits the Pinks With a Bang

Hiru Corp. (OTCMKTS: HIRU) Now Shipping to Clients From its Newly Acquired Roseville, California Manufacturing Facility

Wanderport Corp. (OTCMKTS: WDRP) On the Move as Co Tweets They Have Acquisition Agreement Almost Ready to PR this Week
Trending
-
Uncategorized2 months ago
Meta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider1 year ago
Medium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years ago
Healthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology2 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years ago
SNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma11 months ago
Asia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized3 months ago
Meta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma1 year ago
Humbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
Kell
April 6, 2022 at 9:45 pm
Great article. Rgbp offers a great opportunity.